Stanford Researcher Criticizes FDA Plans To Reduce Oversight Of Off-label Drug Use

My next question is, what's going to happen when "personalized medicine" become mainstay with seeing your physician?

Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine. "The FDA should not suddenly start telling physicians how to practice. Physician judgment is critical, especially when approved therapies have not succeeded. Off-label prescribing can be an important tool in such cases," he said. "But in other cases, off-label prescribing has become first-line therapy even in the absence of strong evidence of benefits and safety. This is problematic."
Drugs approved for depression, schizophrenia and seizures were most likely to be used off-label without adequate support for other conditions.